Unlocking Biotech Value: Navigating Asset Optimisation and The Evolving Ecosystem of Innovation 2025 | Arena International Events Group | 28 May 2025 | Webinar

Why attend?
• The biotech industry is in a transformative phase, with evolving therapeutic areas and innovative funding models reshaping its future. As mergers and acquisitions (M&A) continue to drive investment, identifying the optimal timing for exits becomes crucial in maximising asset value. Our panel will delve into the key catalysts, including the data that influences asset valuation and strategies for successful exits.

• Additionally, they will explore how the evolving ecosystem—comprising emerging therapeutic areas such as gene therapy and immunotherapy, research collaborators like CROs, and new funding models—affects drug development and investment decisions. By examining the interplay between these factors, the discussion will highlight strategies for creating value, reducing risk, and fostering continued innovation in the biotech space.

Learning objectives of this webinar:
• How to identify major market influences underpinning biotech asset valuation and optimal exit strategies.
• The impact of emerging therapeutic areas – such as gene therapy and immunotherapy – on long-term value creation
• How evolving funding models and strategic partnerships shape drug development and investment decisions
• Strategies for navigating M&A trends and reducing risk potential risks, all while maintaining a steady pace of innovation

2025 Speakers

Dr. Will Maier
Senior Vice President & Head of Drug Development Solutions, ICON Biotech

Dr. Liz O’Brien
Therapeutic Expert Oncology, Drug Development Solutions, ICON

Georg Schragel
Director of Business Development, Genmab

Quentin Horgan
Associate Director of Drugs Intelligence, GlobalData

2025 Sponsor

• Icon Biotech